Vertex Pharmaceuticals (WBO:VRTX) Change In Receivables : €-226 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Vertex Pharmaceuticals Change In Receivables?

Vertex Pharmaceuticals's change in receivables for the quarter that ended in Mar. 2024 was €-231 Mil. It means Vertex Pharmaceuticals's Accounts Receivable increased by €231 Mil from Dec. 2023 to Mar. 2024 .

Vertex Pharmaceuticals's change in receivables for the fiscal year that ended in Dec. 2023 was €-77 Mil. It means Vertex Pharmaceuticals's Accounts Receivable increased by €77 Mil from Dec. 2022 to Dec. 2023 .

Vertex Pharmaceuticals's Accounts Receivable for the quarter that ended in Mar. 2024 was €1,650 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Vertex Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2024 was 60.82.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Vertex Pharmaceuticals's liquidation value for the three months ended in Mar. 2024 was €6,028 Mil.

Vertex Pharmaceuticals Change In Receivables Historical Data

The historical data trend for Vertex Pharmaceuticals's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Change In Receivables Chart

Vertex Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-203.04

-183.64

-243.11

-338.52

-77.12

Vertex Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															-84.53	-2.68	-5.72	14.12	-231.47

Vertex Pharmaceuticals Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-226 Mil.

Vertex Pharmaceuticals (WBO:VRTX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Vertex Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	1649.744	/	2475.352	*	91
=	60.82

2. In Ben Graham's calculation of liquidation value, Vertex Pharmaceuticals's accounts receivable are only considered to be worth 75% of book value:

Vertex Pharmaceuticals's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	9357.596	-	4941.136	+	0.75 * 1649.744	+	0.5 * 748.052
=	6,028

Vertex Pharmaceuticals Change In Receivables Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Vertex Pharmaceuticals (WBO:VRTX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (WBO:VRTX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

VRTX:USA VRTX:Mexico 1VRTX:Italy VX1d:UK VX1:Germany VRTX34:Brazil

Address

50 Northern Avenue, Boston, MA, USA, 02210

Website

https://www.vrtx.com

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.